A clinical trial looking the treatment of severe dry eye has reported positive results.

Published in Translational Vision Science and Technology, the research examined the use of the enzyme DNase, which degrades material on the ocular surface, and whether it had the potential to ‘reduce signs and symptoms of dry eye disease (DED).’

A placebo-controlled, randomised trial was conducted on 47 patients with severe DED for eight weeks. DNase eye drops were administered to patients four times a day.

The corneal staining of those in the DNase group showed a ‘statistically significant and clinically meaningful reduction at week eight,’ said the report.

‘The results of this clinical trial support the further development of DNase eye drops for treating DED,’ added researchers.